|
タバタ ツトム
TABATA Tsutomu
田畑 務 所属 医学部 医学科（東京女子医科大学病院） 職種 教授・基幹分野長 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 招待の有無 | 招待あり |
| 表題 | Safety and efficacy of levonorgestrel-releasing intrauterine device in the treatment of atypical endometrial hyperplasia and early endometrial cancer. |
| 掲載誌名 | 正式名：The journal of obstetrics and gynaecology research 略 称：J Obstet Gynaecol Res ISSNコード：14470756/13418076 |
| 掲載区分 | 国内 |
| 巻・号・頁 | pp.1-7 |
| 著者・共著者 | Hirata Toru, Kondo Eiji, Magawa Shoichi, Kubo-Kaneda Michiko, Nii Masafumi, Yoshida Kenta, Maezawa Tadashi, Tabata Tsutomu, Ikeda Tomoaki |
| 担当区分 | 責任著者 |
| 発行年月 | 2022/08 |
| 概要 | AIM:To investigate the recurrence rate, live-birth rate, and treatment outcomes of levonorgestrel-releasing intrauterine device (LNG-IUD) for the management of atypical endometrial hyperplasia (AEH) or Grade-1 endometrial cancer (EC) in patients who desire fertility-sparing treatment and those seeking conservative treatment without fertility preservation.METHODS:We prospectively enrolled nine patients from a single institution between April 2009 and September 2013 who were followed up for 60 months after LNG-IUD insertion.RESULTS:The median patient age was 35 (range: 29-39) years. The overall recurrence rate was 56% (5/9). The median interval between removal of the LNG-IUD and recurrence was 20.5 (range: 2-30) months. Three of the nine patients had Grade-1 EC, and six had AEH. The response rates to the LNG-IUD in patients with Grade-1 EC and AEH were 66% and 100%, respectively. Four patients (three with AEH, one with Grade-1 EC) experienced recurrence 6 months after MPA treatment and all 4 (100%) had complete response. Eight patients desired fertility preservation, of which 37% (3/8) conceived after receiving fertility treatment and 25% (2/8) had a live birth; the remaining three had previously received MPA for 6 months and had a recurrence; of these, 1 had a live birth.CONCLUSION:LNG-IUD is effective for the management of AEH and EC in young patients who desire fertility-sparing treatment, including those ineligible for MPA owing to the presence of comorbidities and those with recurrence after MPA treatment (6-month treatment), and patients seeking conservative treatment without fertility preservation. |
| DOI | 10.1111/jog.15408 |
| PMID | 36054237 |